Free Trial
→ Why The Biggest Names in AI Are Heading To The Arctic (From The Tomorrow Investor) (Ad)tc pixel
NASDAQ:MIRM

Mirum Pharmaceuticals Q3 2026 Earnings Report

Mirum Pharmaceuticals logo
$79.71 -1.72 (-2.12%)
As of 10:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Mirum Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.53
Beat/Miss
N/A
One Year Ago EPS
N/A

Mirum Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$178.06 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mirum Pharmaceuticals Announcement Details

Quarter
Q3 2026
Date
11/3/2026
Time
After Market Closes
Conference Call Date
Tuesday, November 3, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Mirum Pharmaceuticals Earnings Headlines

Mirum Pharmaceuticals (NASDAQ:MIRM) and Sarepta Therapeutics (NASDAQ:SRPT) Head-To-Head Survey
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068483
Mirum wins FDA approval for Atebrioz
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067387
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial
A NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple sclerosis therapy, Lucid-MS, to enter Phase 2 clinical trials - the first time it will be tested in patients with progressive MS. Unlike treatments that suppress the immune system, Lucid-MS is designed to protect myelin, the insulating layer destroyed by the disease. In a pre-clinical mouse model, treatment led to movement recovery including walking. Independent research projects peak annual sales of up to $5 billion if Phase 2 succeeds. The stock still trades under $5 per share.tc pixel
October 6 at 1:00 AM  |  The Tomorrow Investor (Ad)
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, HC Wainwright Analyst Says
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067390
HC Wainwright Issues Positive Forecast for MIRM Earnings
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063706
Mirum Pharmaceuticals, Inc. Meets Primary Endpoint In Phase 3 AZURE-1 Study Of Brelovitug In Chronic Hepatitis Delta Virus
September 29, 2026  |  marketscreener.comM
See More Mirum Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mirum Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mirum Pharmaceuticals and other key companies, straight to your email.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ:MIRM) is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients. The company is also evaluating maralixibat and other investigational therapies in additional cholestatic liver diseases, including primary biliary cholangitis and related conditions.

Founded in 2018 and headquartered in Foster City, California, Mirum serves patients through its commercial operations in the United States and international markets where its products have received regulatory approval. The company’s leadership has included David Meeker, M.D., who has served as chief executive officer and brings experience in rare-disease and specialty pharmaceutical development.

View Mirum Pharmaceuticals Profile
Earnings Tools